Share

September 12, 2017; 89 (11) Editorial

The virtual house call

A 21st-century innovation in the care of patients with Parkinson disease

David R. Shprecher, Jennifer J. Majersik
First published August 16, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004366
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
75

Share

Article Information

vol. 89 no. 11 1103-1104
DOI: 
https://doi.org/10.1212/WNL.0000000000004366
PubMed: 
28814459
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published August 16, 2017.

Article Versions

Copyright & Usage: 
© 2017 American Academy of Neurology

Author Disclosures

    1. David R. Shprecher, DO, MSci and
    2. Jennifer J. Majersik, MD, MS
  1. David R. Shprecher, DO, MSci and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding for Travel and speaker honoraria from: 1.Acadia 2. Arizona Psychiatric Society 3. Baylor College of Medicine 4. Lundbeck Speaker honoraria from: 1. Tourette Association of America Funding for travel from: 1. Huntington Study Group 2. Bristol-Meyers-Squibb 3. Michael J Fox Foundation

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. 1. Teva 2. Lundbeck 3. Acadia

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. I provide telemedicine services for a population that could benefit if findings of this study let to better coverage. Banner Sun Health Research Institute, telemedicine movement disorders clinic, 5% effort, 2017.

    Research Support, Commercial Entities:

    1. 1. Teva 2. Neurocrine 3. Kyowa 4. ADAMAS 5. Intec 6. Biotie 7. Axovant 8. Michael J Fox Foundation 9. US World Meds

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Michael J Fox Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Jennifer J. Majersik, MD, MS
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology, Editorial Board Member, 2015

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Commercial entity: Remedy Pharmaceuticals

    Research Support, Government Entities:

    1. (1) National Institutes of Health, Grant U10 NS086606 - UT StrokeNet, Principal Investigator, 2013-18

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) FAVROS, LCC, expert witness, 2016

  1. From the Cleo Roberts Center (D.R.S.), Banner Sun Health Research Institute, Sun City, AZ; Department of Neurology (D.R.S.), University of Arizona, Phoenix; and the Vascular Neurology Division (J.J.M.), Department of Neurology (D.R.S.), University of Utah, Salt Lake City.
  1. Correspondence to Dr. Shprecher: david.shprecher{at}bannerhealth.com
View Full Text

Article usage

Article usage: August 2017 to May 2022

AbstractFullPdfSource
Aug 2017617012Highwire
Sep 20174361922Highwire
Oct 201714635Highwire
Nov 20174526Highwire
Dec 20173600Highwire
Jan 20187528Highwire
Feb 20184600Highwire
Mar 20183131Highwire
Apr 20184210Highwire
May 20186412Highwire
Jun 20185301Highwire
Jul 20183821Highwire
Aug 20182700Highwire
Sep 20182701Highwire
Oct 20184800Highwire
Nov 20183712Highwire
Dec 20183800Highwire
Jan 20192700Highwire
Feb 20192710Highwire
Mar 20192412Highwire
Apr 20191200Highwire
May 20193111Highwire
Jun 20191311Highwire
Jul 20192200Highwire
Aug 20191810Highwire
Sep 2019900Highwire
Oct 20191110Highwire
Nov 20191300Highwire
Dec 2019610Highwire
Jan 20201000Highwire
Feb 20202000Highwire
Mar 20202453Highwire
Apr 2020930Highwire
May 20202411Highwire
Jun 20201701Highwire
Jul 2020510Highwire
Aug 20201300Highwire
Sep 20202700Highwire
Oct 20204000Highwire
Nov 20201110Highwire
Dec 20201900Highwire
Jan 2021800Highwire
Feb 20211610Highwire
Mar 20211500Highwire
Apr 20213711Highwire
May 20211301Highwire
Jun 20211400Highwire
Jul 20212001Highwire
Aug 20211500Highwire
Sep 2021800Highwire
Oct 20212012Highwire
Nov 20211600Highwire
Dec 20211000Highwire
Jan 20222700Highwire
Feb 20222900Highwire
Mar 20221300Highwire
Apr 20221500Highwire
May 20221810Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me